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Diffuse pulmonary vascular malformations (PAVMs) are a small and understudied, but 
nevertheless important subset of the PAVM population of patients, associated with significant 
mortality and morbidity.  
A review of literature was undertaken to investigate the current understanding of diffuse 
PAVMs. This review demonstrated that no additional attempts to define diffuse PAVMs and describe 
their natural history was made before or after the in 2000 report by Faughnan et al {{51 
Faughnan,M.E. 2000; }}.  
To further expand the findings from 2000, we performed a retrospective review of 36 patients 
(21 female, 15 male) with diffuse PAVMs from a cohort of 821 consecutive patients with PAVMs. 
Diffuse PAVMs were classified angiographically as involving one or more segmental pulmonary 
arteries in one or both lungs.  The following data were noted from the chart review: Hereditary 
Hemorrhagic Telangiectasia (HHT) status, gender, age at presentation, presence or absence of large 
focal PAVMs, oxygen saturations, morbidity and mortality.  
Twenty nine out of 36 (81%) patients had HHT. Diffuse PAVMs were more commonly 
bilateral 26/36 (72%) than unilateral 10/36 (28%) (p=0.02). Initial O2 saturations of patients with 
unilateral and bilateral diffuse PAVM were 87% ± 7% and 79% ± 8% (p=0.02), which the current 
values are 95% ± 3% and 85% ± 7% (p < .0001) respectively. Nine deaths occurred, but only in 
patients with bilateral involvement. Deaths were due to hemoptysis from bronchial artery hypertrophy 
(2), brain hemorrhage (1) and abscess (1), spontaneous liver necrosis (3), operative death during 
attempted lung transplantation (1), and hemorrhage from duodenal ulcer (1).  
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INTRODUCTION 
Hereditary Hemorrhagic Telangiectasia (HHT), also know as Osler-Weber-Rendu 
syndrome is a clinically and genetically diverse multisystemic vascular disorder (1). The 
manifestations of HHT are a result of abnormal vasculature, characterized by lack of 
capillary networks resulting in direct arteriovenous connections and fragile dilated 
vessels of various sizes. Telangiectases are small vascular lesions found on the face, lips, 
hands, as well as oral, nasal and GI mucosa(1). Arteriovenous malformations (AVMs) are 
larger vascular lesions found most commonly in the lung (2), brain(3), liver (4) , or GI 
tract(5), and less commonly spinal cord(6).  
HHT is a condition with an equal gender distribution, affecting all races and ethnic 
groups worldwide. The prevalence of HHT appears to be more common than previously 
thought. The reported incidence rates vary from country to country, and are found to be 
anywhere from 1 in 2351 in the French region of Ain (7), 1 in 3500 on the Danish island 
of Funen (8), 1 in 5155 in the Leeward Islands (9), 1 in 5,000-8,000 in the region of Akita 
in Japan (10), 1 in 16,500 in Vermont (11), and 1 in 39,216 in northern England (12). The 
general lack of public and physician awareness about HHT makes it a highly under-
diagnosed condition.  
HHT was first recognized toward the end of the 19th century as a genetic disorder 
causing nosebleeds, GI bleeding, and abnormal vascular structures. The first known 
report describing what is now known as hereditary hemorrhagic telangiectasia dates back 
to 1864 from Sutton’s report of epistaxis as a result of degeneration of the vascular 
system (13). In 1896, Rendu distinguished the disease from hemophilia, and reported the 
association of epistaxis, cutaneous telangiectasia, and familial occurrence (14). A number 
   2 
of case reports followed, including those by Osler (15)and Weber (16) further describing 
the disorder. These resulted in the eponym Osler-Weber-Rendu syndrome. However, the 
often preferred term “hereditary hemorrhagic telangiectasia” was coined in 1909 by 
Hanes (17), as an acknowledgement of the three features that defined the disorder at the 
time. 
Currently, the clinical diagnosis of HHT is established according to the Curaçao 
criteria, as described by Shovlin et al (18), where fulfillment of three out of the four 
criteria is required for a definite clinical diagnosis of HHT:  
1. spontaneous recurrent nosebleeds (epistaxis) 
2. mucocutaneous telangiectases 
3. visceral AVMs 
4. positive family history 
If only two criteria are present, the diagnosis of HHT is possible or suspected, and if less 
than two are present, the diagnosis is unlikely.  
 
Genetics 
HHT is a genetically heterogeneous autosomal dominant disorder with incomplete 
penetrance and age-related expressivity. Lethality of the homozygous condition is 
generally accepted, given the studies demonstrating lethality of homozygous ENG and 
ALK1 knockout mice, which die in the embryonic stage at mid-gestation, as well as the 
absence of conclusive reports on living homozygous individuals (19).  
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Five genotypes have been identified to date in HHT patients (Figure 1). The two 
main types of HHT, type 1 and type 2, are caused by mutations is the following genes, 
respectively: 
1. ENG - localized on chromosome 9, encodes endoglin, a type III TGF-β receptor 
(20) 
2.  ALK-1 - localized on chromosome 12, encodes the activin receptor-like kinase 1, 
a type I TGF-β receptor (21).  
Recently, mutations were identified in several other genes: SMAD 4 - a gene 
localized on chromosome 18, in families with both HHT and juvenile polyposis (22), as 
well as two unidentified genes- on chromosome 5 (HHT 3) (23) and chromosome 7 
(HHT 4) (24). 
Several studies investigating the prevalence of ENG and ALK-1 mutations in HHT 
have shown conflicting results (25-28). The most recent study investigating this topic 
included the largest series of patients reported to date and has shown predominance of 
ALK-1 over ENG mutations (29). 
Currently, genetic testing for HHT is available on a clinical basis for mutations in 
endoglin and ALK-1. Genetic testing for SMAD 4 is only available as a research test, and 
will be soon available clinically. A study by Cohen et al (30) has recently shown that 
genetic screening with targeted clinical protocol is more economically attractive than the 
conventional clinical screening, resulting in a reduction in the number of clinical tests for 
family members who do not have HHT. Therefore, once an individual with HHT is 
identified, screening and genetic counseling should be offered to the family.  
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Pathogenesis  
The corresponding ENG and ALK-1 proteins are specific endothelial receptors of 
the TGF-β superfamily essential for maintaining vascular integrity (19). Generally, type 
II TGF-ß receptors or accessory proteins (ENG) bind the ligand, subsequently forming a 
complex with type I receptors (ALK-1), which then activate downstream cytoplasmic 
signaling molecules including SMADs. SMADs translocate to the nucleus and modulate 
gene transcription(31). Therefore, it is expected that the abnormal vessels in HHT 
develop because of aberrant TGF-ß signaling at some stage during vascular development 
and homeostasis. 
It has been shown that endothelial cells derived from HHT1 or HHT2 patients 
express approximately one half of the normal endoglin or ALK-1 levels, respectively(32, 
33), and that endothelial cells derived directly from AVMs also express half the normal 
levels of endoglin(34). Therefore, the current understanding is that HHT results from 
endoglin or ALK-1 haploinsufficiency (lack of sufficient protein for normal function), 
rather than from a “second hit” (additional local loss of endoglin expression).  A 
complicated series of processes seems to be involved in the development and remodeling 
of blood vessels, and in addition to genetic factors, environmental factors might play an 
important role. Present knowledge about the function of endoglin and ALK1 in 
endothelial cells and the current haploinsufficiency model have suggested that the future 
therapeutic perspectives for HHT might include an increased expression of either 
endoglin or ALK1 (19). However, as the exact pathogenesis of HHT continues to be only 
speculative, it is still early to consider gene therapy as a treatment or prevention option. 
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Genotype-Phenotype Correlations 
Significant clinical variability is observed in HHT, with both intra- and inter-
familial variations in age-of-onset, localization of lesions, and severity of complications. 
Genotype-phenotype correlations have been studied, but are still limited.   
HHT type 1: 
• earlier onset of epistaxis (35) 
• higher number of PAVMs (35-37) 
• higher number of CNS vascular malformations(35, 38) 
HHT type 2: 
• increased incidence of  hepatic AVMs (35, 39, 40) 
• reduced penetrance, lower expressivity, and a later age-of-onset (41) 
All manifestations of HHT have been reported in both types, with the exception of 
rare reports of primary pulmonary hypertension (42, 43) and spinal AVMs (35), which 
have only been reported in HHT2.  
The frequency of mucocutaneous telangiectases in different age groups appears to be 
similar in patients with either HHT1 or HHT2. By age 40, multiple telangiectases in one 
or more of the characteristic locations (hands, face, mouth) are found in 100% patients 
(35).  
Furthermore, the predominance of HHT1 or HHT2 is thought to correlate with 
geographical location. While HHT1 is predominant in North America, Canada and 
Northern Europe, HHT2 is more abundant in the Mediterranean countries such as Italy, 
Spain and France (19).   
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Women and HHT 
Women seem to be at an increased risk of developing PAVMs, as well as possibly 
hepatic involvement and cerebral hemorrhage (44). This may reflect a modification of the 
HHT vasculature by female hormones, as well as hemodynamic changes during 
pregnancy. These hormonal effects have been supported by the successful treatment of 
gastrointestinal bleeding in HHT patients using combined estrogen-progesterone 
therapy(45), a report of progesterone receptors in vessels of HHT patients (46), and 
variations in epistaxis during the menstrual cycle and menopause(47). 
 
Clinical Manifestations of HHT 
Manifestations of HHT are generally not present at birth, rather they develop with 
increasing age. An important exception are cerebral AVMs which have been described as 
early as during the neonatal period, representing a significant cause of mortality and 
morbidity in children with HHT (48, 49). Epistaxis is usually the earliest manifestation of 
disease, often occurring in childhood, pulmonary AVMs becoming apparent from 




The most common manifestation of HHT is recurrent epistaxis, a result of the 
fragility and subsequent spontaneous bleeding from nasal mucosal telangiectases(1). 
While some patients only have occasional nosebleeds, others experience significant 
bleeding on a daily basis. Many patients require no treatment other than iron 
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supplementation, whereas others may require transfusions and emergency nasal packing. 
A number of topical, systemic, and surgical treatments are available for the treatment of 
epistaxis in HHT, but the principle of “doing as little as possible for as long as possible” 
seems to be the best, except in cases of HHT patients experiencing massive hemorrhage 
or daily nose bleeds (31). 
 
Skin 
Mucocutaneous telangiectases occur in about 75% of individuals occurring mostly 
on the face, lips, tongue and buccal mucosa, as well as fingertips (50). They typically 
present later in life than epistaxis, from about the second or third decade of life, 
increasing in size and number with age (50). They may bleed but this is rarely clinically 
important and the main concern is cosmetic, when short term benefits of laser or other 
ablation therapies may be obtained(31). 
 
GI tract 
Recurrent gastrointestinal tract hemorrhage occurs in about 25-33% of HHT 
patients, with a late onset, usually from the fifth or sixth decade (5, 50), and may result in 
severe anemia and blood transfusion requirements. Anemia out of proportion to epistaxis 
is often a presenting sign of GI hemorrhage (5). Distinguishing between epistaxis and GI 
bleeding can be challenging, given that many HHT patients are placed on iron 
supplementation that causes dark stools, making it difficult to detect a GI bleed. Epistaxis 
can also mimic GI bleeding upon swallowing of nasal blood (5). The extent of 
telangiectases, which are most commonly found in the stomach, duodenum and jejunum, 
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was found to correlate with the severity of a patient’s anemia and transfusion requirement 
(5).  
Treatment of HHT-related GI bleeding can be challenging. Most patients are 
managed conservatively with oral iron supplementation and, if necessary, blood 
transfusions.  Other therapies include lasers and cautery, as well as various 
pharmacologic agents. The only pharmacologic therapy supported by randomized 
controlled trials is the use of female hormones in heavily transfusion-dependent 
patients.(45). Others include danazol (a weak androgen) and aminocaproic acid (inhibits 
fibrinolysis), both only supported by case reports (51-53). Risks and benefits should be 
carefully weighed in the decision to use drug therapy, taking into account the number of 
telangiectases and severity of bleeding versus potential side effects of treatment (5). If 
present, PAVMs should be repaired before initiation of hormonal therapy. Endoscopic 
treatment of asymptomatic telangiectases is not warranted, and surveillance endoscopy is 
unlikely to benefit patients if they show an improvement with treatment (5).  
 
Liver 
Although the majority of patients with HHT have hepatic vascular malformations, 
symptoms occur in only a minority, around the age of 30, and with clear female gender 
predominance (54). The symptoms of liver involvement in HHT are associated with 
blood shunting (arteriovenous, arterioportal, or portovenous), and fall into one of three 
categories: high output heart failure, portal hypertension, or biliary disease (4). 
A clinical suspicion of hepatic involvement should be raised in an HHT patient with 
shortness of breath and/or edema without  PAVMs or anemia, or those with ascites, 
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variceal hemorrhage, abdominal pain, encephalopathy or cholangitis. In either case, a 
physical examination finding of a bruit or thrill in the RUQ or epigastrium supports the 
diagnosis (54). Hepatomegaly and/or abnormal liver function tests may be present, as 
well.   
A definite diagnosis of liver involvement is made with various imaging studies, 
including angiography (4), computed tomography (55) , MRI (56), or Doppler 
sonography (57). According to consensus recommendations from the HHT Scientific 
Meeting in Lyon in April 2005(58), Doppler ultrasound is sufficiently accurate and 
should be the first-line imaging of the liver in the general HHT population, but only in 
those in whom liver involvement is suspected. Liver biopsy in any patient with HHT is 
considered unnecessary and should be avoided (58).  According to the same consensus 
recommendations, liver transplantation should only be considered after failure of 
intensive medical therapy, and embolization of liver vascular malformations is a high-risk 




Brain malformations in HHT include mainly telangiectases and cerebral AVMs 
(CAVMs). Most complications arise from CAVMs, which are thought to affect more than 
10% of HHT patients(3, 31). They can lead to headache, seizures, ischemia of the 
surrounding tissue due to a steal effect, or hemorrhage. CAVMs can cause symptoms as 
early as during the neonatal period. In 2002, the first neonatal case of intracranial 
hemorrhage (ICH) secondary to a CAVM was reported in a patient who was 
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subsequently found to have HHT (48). In addition, the same group reported 8 more 
infants and children, ages 4 weeks to 16 years, who also presented with ICH secondary to 
CAVMs. Before these hemorrhages, none of the children were suspected of having HHT, 
despite a family history of the disease, demonstrating that infants and children with a 
family history of HHT are at risk for sudden and catastrophic ICH. Another study of 
arteriovenous fistulas (AVFs) in 41 children, demonstrated that even though cerebral 
AVFs are a rare disease, they are not infrequently seen in neonates and infants with 
AVMs, and that HHT is suspected to be present in about one fourth of these patients (49). 
Therefore, screening for CAVMs (Figure 2) with a single baseline MRI may potentially 
identify and prevent more serious sequelae (59). Neurovascular surgery, embolization 
and stereotactic radiosurgery may be used to treat CAVMs (1). 
It is important to note that neurological symptoms occur not only due to cerebral or 
spinal AVMs, but also even more commonly with pulmonary AVMs. PAVMs can lead to 
cerebral abscess (9%) or TIA/stroke (24%) due to right-to-left shunting that facilitates the 
passage of paradoxical emboli into the cerebral circulation. But, the most common 
neurological manifestation of PAVMs is migraines (43%) (60). Several hypotheses have 
been formulated in explaining the increased prevalence of migraines in patients with 
PAVMs (61).  A causal relationship between the presence of a right-to-left shunt and 
migraines has been suggested, and supported by a study which demonstrated a decreased 
prevalence of migraines in HHT patients that underwent embolization of PAVMs(62). 
Trigger substances, such as serotonin or micro emboli, instead of being trapped in the 
pulmonary capillaries might enter the systemic circulation via the shunt, resulting in 
cerebral vascular instability and causing migraine (63).  
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Lung 
Together with the brain AVMs, pulmonary AVMs are the greatest cause of 
mortality and morbidity in HHT patients. It is not surprising then that the lung is the best 
studied organ involved in HHT to date. PAVMs are a marker for HHT, since about 85-
90% of people with PAVMs have HHT (2). PAVMs are present in about 30% of patients 
with HHT, although the incidence varies depending on the specific genetic mutation 
present (64). PAVMs are more common in females, which may relate to effects of female 
hormones on HHT vasculature (44). 
PAVMs are dilated, thin-walled vessels that replace normal capillaries between the 
pulmonary artery and vein (65).  The presence of this high-flow low-resistance circuit 
gives rise to right-to-left shunting of deoxygenated blood, resulting in hypoxemia, and 
manifesting as clubbing, cyanosis and dyspnea. Orthodeoxia, a further decrease in 
oxygen saturation on assuming an upright posture, is common in HHT patients with 
PAVMs, and is attributed to increased flow of blood under the influence of gravity 
through shunts situated at the lung bases (44). 
The loss of filtering capacity provided by pulmonary capillaries produces a conduit 
through which paradoxical emboli can pass into the systemic circulation, causing 
catastrophic neurological complications such as stroke and cerebral abscess. Neurological 
sequelae occur in about 40% of adults with untreated PAVMs, with approximately 30% 
of patients having a history of stroke, and 10% of brain abscess. Hemorrhagic 
complications include pulmonary or pleural hemorrhage and hemoptysis, and occur in 
about 10-15% of HHT patients with PAVMs(60, 66).  
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The angioarchitecture of PAVMs has been extensively studied in adults (2, 60, 67, 
68).  PAVMs are classified as focal (95%) or diffuse (5%) (67, 69). Focal PAVMs were 
further classified as simple (90%) or complex (10%)(2). A PAVM is considered simple 
when it is fed by one or more branches from the same pulmonary segmental artery. If 
more than one segmental artery is involved, the PAVM is considered complex. As 
originally characterized by Faughnan et al in 2000 (69), diffuse PAVMs are defined as 
involving all segmental arteries of at least one lobe of the lung. These patients are usually 
deeply cyanotic and have a greater predisposition to neurological complications. 
The presence (but not size, location or number) of PAVMs is detected with high 
sensitivity and specificity using contrast echocardiography (CE), which is accompanied 
by injection of agitated saline solution. In normal individuals, all the microbubbles 
formed are filtered out by the pulmonary capillaries, and none should appear in the left 
side of the heart. In the presence of an intracardiac shunt (e.g. PFO, ASD or VSD), 
bubbles will appear in left cardiac chambers almost immediately after filling the right 
heart chambers. If there is a shunt at the pulmonary level (e.g. PAVM), bubbles will be 
seen in left cardiac chambers 2-3 cardiac cycles after filling the right heart chambers (64). 
A significant proportion of patients, presumably those with PAVMs that are too small, 
will have shunting identified on echocardiography, but not on CT or even pulmonary 
angiography (44).  These patients are still advised to use antibiotic prophylaxis and 
follow-up CT scanning on the assumption that PAVMs are present (Figure 3). 
Together with pulse oximetry (considered positive if oxygen saturation < 97%), CE 
has replaced shunt studies and non-contrast CT as initial screening methods. If either CE 
or pulse oximetry are positive, thin section non-contrast CT is used to determine the size 
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and type of PAVMs, which are included in the treatment criteria. In children, 
measurement of supine and upright oxygen saturation can be used for screening for 
PAVMs, with CE generally used after the age of 12, or earlier in cases when pulse 
oximetry is low, growth failure or difficulty with physical activity are present (70). In 
addition, exercise testing is currently being developed at Yale as an alternate screening 
method for PAVMs in children, in which a drop in oxygen saturation on exercise is 
indicative of the presence of significant PAVMs. 
Before 1980, surgery was the only method of treatment; ligation, local excision, 
segmentectomy, lobectomy, or pneumonectomy was performed in most cases (2). 
Surgical resection may still have a role in patients in whom right-to-left shunting persists 
after embolization of all feasible vessels (44), or if a patient has severe contrast allergy, 
precluding angiography. Embolization therapy, first described by Porstmann in 1977 
occludes the feeding arteries to a PAVM (71). Treatment using transcatheter 
embolotherapy (TCE) can prevent many of the debilitating and life-threatening 
complications of simple and complex type PAVMs, such as exercise intolerance due to 
hypoxemia, prevention of neurological complications and prevention of lung hemorrhage 
(2). TCE is a safe and efficient non-surgical procedure, which avoids major surgery, 
general anesthesia, and loss of pulmonary parenchyma. It is currently recommended for 
all pulmonary AVMs with a feeding artery 3 mm (60, 68, 72). The procedure is 
technically successful in over 98% of cases (71). Outcomes in children are as successful 
as in adults, with similar complication rates (70). Long-term follow-up is warranted after 
transcatheter vaso-occlusion of PAVMs due to frequent recanalization of treated PAVMs 
and development or growth of untreated PAVMs. 
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More difficult are the treatment considerations for patients with diffuse PAVMs. 
Lung transplantation has been tried unsuccessfully (unpublished), with no long-term 
outcome data available to date. Redistribution of pulmonary blood flow, by occluding the 
segmental arteries of an entire lobe has been used successfully and with improvement in 
oxygenation.  Unfortunately, a late complication, such as hemoptysis due to bronchial 
artery hypertrophy has made this approach not ideal. One of the goals of this report is to 
propose a new treatment approach, which we hope will improve oxygenation and 
decrease the rate of hemoptysis in this subset of patients.  
 
STATEMENT OF PURPOSE AND HYPOTHESIS 
 A small subset of patients with PAVMs has a more severe and diffuse pattern of 
disease. These patients have a greater predisposition to neurological complications 
compared to patients with focal PAVMs, and are more difficult to treat. 
Before 2000, little was known about the clinical characteristics, course and 
management of this subset of patients. In 2000, Faughnan et al defined diffuse PAVMs 
and described the natural history of 16 patients with this subset of PAVMs (69). Since 
then, little investigation has been done in this field.  
The purpose of our study was multi-faceted: 
1. To further describe the natural history of patients with diffuse PAVMs 
2. To perform a review of the English-language literature on diffuse PAVMs, 
focusing on how this subset has been defined to date  
3. To develop a new anatomical classification of diffuse PAVMs and describe a new 
treatment approach. 
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We hypothesize that the lung of patients with diffuse PAVMs is focally diffuse, 
such that some areas of an affected lobe are more diffuse than others.  For example, the 
right lower lobe has 5 bronchopulmonary artery segments. If 2 of 5 are diffusely 
involved, then perhaps occluding these 2 more severely affected segments from 
peripheral to central might show effective palliation (i.e. raise room air oxygenation of 
the patient). Developing a new classification of the lung in patients with diffuse PAVMs 
would aid in assessing whether occlusion of lung sub-segments with the most diffuse 
involvement improves their oxygenation.  
 
SUBJECTS AND METHODS 
Literature Review 
 Case reports and reviews of patients with diffuse PAVMs were searched using 
Medline and PubMed databases. Old reports that were not present in online databases 
were identified by examining article references. Only reports in which diffuse PAVMs 
were diagnosed by angiography or CT scan were considered to be properly classified as 
diffuse. We believe that the diagnosis of diffuse PAVMS cannot be made correctly by 
examining pathological specimens, so those reports were excluded.  
 
Subject Selection, Demographics and Clinical Characteristics 
 36 patients with diffuse PAVMs were included in this study, from a cohort of 821 
consecutive patients seen by Robert I. White, Jr. between May 1978 and December 2006.  
15 of the 16 patients with diffuse PAVMs originally reported in the 2000 paper by 
Faughnan et al were followed in this study. The rest of our cohort consisted of the 
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additional 21 patients seen at the Yale Vascular Malformation Center or at the University 
of Bari HHT Center. A retrospective review of medical records and images was 
performed, after obtaining informed consents and an IRB approval. The following data 
were collected:  
• HHT status - the diagnosis of HHT was made according to the Curaçao criteria, as 
presented by Shovlin et al (18) 
• Gender 
• Age at presentation 
• Presence or absence of large focal PAVMs (≥ 3mm diameter artery) 
• Degree of diffuse involvement - all patients underwent diagnostic pulmonary 
angiography, including measurements of pulmonary artery pressures; patients 
were divided into 2 categories based on unilateral or bilateral lung involvement by 
diffuse PAVMs, as well as the extent of each lung involvement as > or < than 
50% 
• Oxygen saturations 
• Complications 
o of the disease - brain abscess, TIA/stroke 
o of embolotherapy- pleurisy, angina, coil migration 
It is still unclear whether hemoptysis is a part of the disease itself, or a 
complication of embolotherapy; regardless, it was included in this study as an 
important complication. 
• Years of follow-up - calculated from the date of first visit to the date of last visit 
or death 
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• Survival 
  
Definition of Diffuse PAVM 
 Faughnan et al defined diffuse PAVM as involving all segmental branches of one 
lobe (18).  We believe that one lobe can be involved to different degrees, not necessarily 
involving all the branches. Therefore, we felt that a more precise classification of the 
diffuse subset of PAVMs was necessary. In our study, involvement was defined as 
diffuse is at least 1 out of the 18 lung segments was diffusely affected (Figures 4 and 5). 
Furthermore, if more than 5 out of 10 right lobe segments, or 4 out of 8 left lobe 
segments were affected, the extent of involvement was considered more than 50%.  
Unlike the patients with multiple focal PAVMs (Figure 6), involving one or more 
segmental arteries, which are successfully treated with transcatheter embolotherapy 
(TCE), response to treatment in patients with diffuse PAVMs is less satisfactory, with a 
minimal rise in oxygen saturation after TCE. It is therefore important to distinguish 
between multifocal (i.e. multiple focal) and diffuse PAVMs, which is often uncertain 
until a post-occlusion angiogram is obtained. 
 
Transcatheter Embolotherapy 
 The technique of embolotherapy performed at the Yale Vascular Malformation 
Center has evolved in the past decade, as the increased frequency of hemoptysis from 
bronchial arterial hypertrophy has been noted.  The enlargement of bronchial arteries and 
collateral filling of distal pulmonary arteries are likely a consequence of occlusion of 
bronchial arteries by the central approach. Therefore, the technique was empirically 
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changed from central to peripheral, blocking only the most severely affected segments 
from distal to proximal with tightly packed fibered coils. This peripheral approach is 
expected to exclude the diffusely involved segmental arteries from the pulmonary 
circulation, thus redistributing the pulmonary blood flow to less involved or unaffected 
segments of the lung. All patients were heparinized during embolotherapy because of a 
thrombophlebitis in a previously reported patient (69). 
  
Statistical Analysis 
 T-tests (continuous data) and chi-square (categorical data) analyses were used for 
comparing subjects with unilateral versus bilateral disease. Patient data were entered in 
an ACCESS database and imported in Statistical Analysis Software (SAS, Version 9.1; 





About 5% of patients with HHT have a more severe and diffuse pattern of lung 
involvement, however, little is known about the clinical characteristics, course and 
management of these patients. A single attempt to assess the natural history and 
appropriate management of these patients has been made to date (69). The rest are case 
reports (73-95). From 1950 to 2007, over 50 patients have been reported as having 
diffuse PAVMs (also described as “multiple microscopic fistulae”, “dispersed 
telangiectasia”, “diffuse pulmonary telangiectasia”), excluding our cohort, and those with 
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hepatopulmonary syndrome. In addition, at least 10 more diffuse cases from foreign-
language publications were identified through English-language reviews or author’s 
translations in PubMed. Out of all these cases, only a minority used appropriate 
diagnostic tools (many inappropriately diagnosed diffuse PAVMs from pathology 
specimens; others were in fact multifocal rather than diffuse), and matched our definition 
of diffuse PAVMs. 
Prior to the modern era, two papers defined diffuse PAVMs- Higgins and Currarino 
(76, 96), both in 1976 as “pulmonary telangiectasia, in which innumerable minute 
pulmonary arteriovenous fistulae between peripheral branches of the pulmonary arteries 
and veins are distributed diffusely throughout both lings”. In 2000, Faughnan et al 
redefined the diffuse subset as “AVMs involving every subsegmental artery of at least 
one lobe” (69).  Since 2000, very little has been published on patients with diffuse 
PAVMs.   
The majority of patients with diffuse PAVMs have HHT, generally present with 
severe cyanosis and exercise intolerance, and appear to have a poor prognosis. Since 
occlusion or resection of all AVMs in these patients is not a realistic treatment approach, 
most of the reported patients have gone untreated. Prior to Faughnan’s study, little was 
known about the risk of hemorrhagic and neurological complications in these patients. 
Faughnan demonstrated that neurological rather than pulmonary complications are the 
rule in this patient population. The incidence of neurological complications is higher in 
patients with diffuse than in those with discrete PAVMs, such that brain abscesses have a 
prevalence of 38% (69), as opposed to 9% in those with discrete PAVMs (60). This is not 
surprising, since diffuse involvement may include hundreds of AVMs. Embolization of 
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PAVMs in these patients does not improve the hypoxemia (as many untreated PAVMs 
remain), but may reduce the risk of neurological sequelae. Therefore, these patients have 
a fairly good prognosis with appropriate management, which should include 
embolotherapy of larger AVMs, and life-long antibiotic prophylaxis for bacteremic 
procedures. 
In terms of pulmonary complications, these patients don’t tend to develop 
spontaneous hemothorax, but can develop hemoptysis, often secondary to bronchial 
artery hypertrophy (69). It is not known whether this hypertrophy is part of the disease 
process or whether it develops subsequent to TCE. In terms of daily functioning, these 
patients lead fairly normal lives, adapting to chronic hypoxemia by mainly unknown 
mechanisms. Polycythemia, which likely helps compensate for hypoxemia, is present in 
the majority of these patients. Pulmonary artery pressures are normal or decreased, likely 
because of decreased pulmonary vascular resistance secondary to the diffuse AVMs. 
Some might expect development of pulmonary hypertension in these patients, secondary 
to chronic hypoxia. However, since hypoxic vasoconstriction occurs secondary to 
alveolar hypoxia (which is not present in these patients) rather than hypoxemia, these 
patients generally do not develop pulmonary hypertension.  
When confronted with a patient with diffuse pulmonary AVMs, a clinician might 
incorrectly presume a poor prognosis and suggest referral for lung transplantation (74). 
However, the 2-year survival rate in the group presented by Faughnan et al that was 
treated with TCE (91%) was better than that seen after lung transplantation (70%) (97). 
Therefore, referral for lung transplantation has so far not been justified.  
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Multi-Center Diffuse PAVM Series 
General Characteristics 
Since 2000, when we reported 16 patients with diffuse PAVMs, we have now 
extended our database with additional 21 patients, and followed 15 out of the 16 
previously reported ones. These 36 patients (21 female, 15 male) were chosen out of 821 
consecutive patients (4.4%) because of their diffuse PAVM involvement, with one or 
more segmental pulmonary artery affected.  Mean age at presentation was 35.4 ± 17.8 
years, with a mean follow-up of 8.5 ± 6.1 years, and a range of 0.12 to 26 years. HHT 
was present in 29/36 (81%), and the morphology of PAVMs was consistent with HHT 
and different from the type seen in hepatopulmonary syndrome. (98). Nine out of 35 
(25%) died during the follow-up period, all of which had bilateral involvement. No 
deaths occurred in patients with unilateral involvement, and this difference is statistically 
significant (p=0.03).  
Unilateral Diffuse PAVM Patients (Tables 1 and 3) 
Unilateral involvement was found in 10/36 patients (28%); 2 were female and 8 
were male, 7 of them with HHT. Two of the 10 patients were seen prior to 1998 (69), and 
their mean age of first visit was 21 ± 11 years (range 4 to 37) with mean follow-up time 
of 5.7 ± 4.8 years (range 0.12 to 16).  Three of the 10 patients (30%) had complications at 
the time of their initial presentation, including brain abscess (2) and hemoptysis (1). 
Since 1998, 3 patients have had significant complications, but have all recovered. All 10 
patients have remained fully functional, working or attending school fulltime.  
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Bilateral Diffuse PAVM Patients (Tables 2 and 4) 
Bilateral involvement was found in 26/36 patients (72%); 19 were female, 7 were 
male, and 22 of them had HHT. Thirteen of the 26 patients were seen prior to 1998 (69). 
The mean age at time of first visit was 24.8 ± 17.9 years (range 0.5 to 71) with the mean 
follow-up time of 9.6 ± 6.3 years (range 0.4 to 26 years). Nineteen of the 26 patients 
(73%) had complications at the time of their initial visit, including a single brain abscess 
(7), two brain abscesses (2), single TIA/stroke (9), two strokes (1). Of the 17 patients 
living, 14 are working or attending school fulltime, and 3 are considered disabled.  
Transcatheter Embolotherapy 
 Two of the 10 (20%) patients with unilateral diffuse PAVM and 17/26 (65%) 
patients with bilateral diffuse PAVM involvement also had focal PAVM (p=0.02) 
(Tables 3 and 4). In these patients, only involved arteries with a diameter ≥3mm were 
occluded as close to the fistula (peripherally) as possible (72). 
 In the severely symptomatic patients, peripheral to central occlusion of diffusely 
involved segments was performed using standard coil techniques (Figure 7) (99). Oxygen 
saturation values for patients with unilateral and bilateral diffuse PAVMs were initially 
87% ± 7% and 79% ± 8% (p=0.02), and most recently 95% ± 3% and 85% ± 7% (p 
<0.0001), respectively (Tables 3 and 4).  
 Six of the 36 patients underwent angiography and measurements of pulmonary 
pressures, but without TCE. Three of those had no rise of 10mm or more of PaO2 upon 
temporary occlusion of lower lobe pulmonary arteries, and were therefore not considered 
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to be candidates for embolization. The other three patients did not require TCE because 
they were relatively asymptomatic.  
Complications 
None of the patients had pulmonary hypertension, although some had elevated 
pulmonary artery and left atrial pressures secondary to liver disease.  
Thirteen of the 30 patients that underwent TCE had early complications post- 
embolization with full recovery, including self-limited pleurisy in 11/12 and transient 
angina in 1/12 (most likely sue to introduction of air embolus during TCE). Coil 
migration did not occur in any of our patients.  
Hemoptysis 
Six of the 36 patients developed hemoptysis sometime during their course: one with 
unilateral and one with bilateral before treatment, and four late after treatment (Tables 1 
and 2).  
A. Hemoptysis in Patients with Unilateral Diffuse PAVM 
Two patients with unilateral involvement developed hemoptysis- one before and 
one after embolization. The first one (Patient 5) had a viral URI causing severe 
hemoptysis, and was treated successfully by bronchial artery embolization. She continues 
to be aggressively treated with antitussives to prevent recurrence secondary to hard 
coughing. The second patient (Patient 8) has developed recurrent hemoptysis, either 
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spontaneous or with URIs, after initial TCE treatment of 3 segments of the right lower 
lobe. 
B. Hemoptysis in Patients with Bilateral Diffuse PAVM 
Hemoptysis was present in 4/26 patients. The first patient (Patient 12) developed 
massive hemoptysis and was treated by bronchial artery embolization, but in 2003 and 
2005 developed hemoptysis again and died (69, 100). The second one (Patient 14) had 
not been treated (69).  The third patient (Patient 18) had massive hemoptysis, was 
evaluated at another institution, and underwent a successful partial right lower lobe 
lobectomy without recurrence of hemoptysis in 8 years. The fourth patient (Patient 20) 
had recurrent spontaneous as well as URI-induced hemoptysis related to hard coughing. 
Diffuse telangiectases were demonstrated in this patient with bronchoscopy. His 
hemoptysis spontaneously resolved after 1996, with no recurrence.   
Mortality 
None of the patients with unilateral diffuse involvement died during 27 years of 
follow-up. Nine deaths occurred in the group of 26 patients with bilateral diffuse 
involvement. Six of these deaths occurred during the interval follow-up, and were 
secondary to brain abscess (Patient 13), brain hemorrhage (Patient 25), hemoptysis 
(Patient 12), and three from liver complications (Patient 17, 19 and 27)- subacute liver 
hemorrhage and biliary necrosis (2) and ammonia intoxication (1).   
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The mean age at fist visit of patients who died was not significantly different from 
those still living- 25 ± 16 years versus 24 ± 23 years (p=0.22). Neither were the oxygen 
saturations- 78% ± 7% versus 82% ± 9% (p=0.18).  
DISCUSSION 
Pulmonary arteriovenous malformations can cause hypoxemia, pulmonary 
hemorrhage, and serious neurological complications, such as stroke or brain abscess. 
About 5% of patients with PAVMs have a more severe and diffuse pattern of disease. 
Little was known about the clinical characteristics, course and management of these 
patients prior to the study by Faughnan et al in 2000 (69). Before that only case reports 
appeared in the literature (73-95).  Faughnan et al studied the natural history of 16 
patients with diffuse PAVMs, and concluded that these patients are at increased risk of 
neurological complications, and that transcatheter embolotherapy does not significantly 
improve their profound hypoxia, but may reduce the risk of neurological complications.   
Since then, very little has been published about these patients. Because patients 
with diffuse PAVMs are associated with significant morbidity and mortality, more 
frequent monitoring is required(69). In addition, we observed that hemoptysis, which is 
rarely seen in patients with focal PAVMs, is a frequent finding in patients with diffuse 
PAVMs. This is consistent with the finding that diffuse involvement is associated with 
more complications, but we also began to question our treatment approach as a possible 
cause of hemoptysis. Since Faughnan’s paper, the Yale technique has empirically 
changed from proximal to distal occlusion, treating only the most severely affected 
segmental arteries, as opposed to occluding the entire lobe proximally, in hopes of 
preventing bronchial artery hypertrophy and, hence, hemoptysis. The need to re-classify 
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the anatomy of diffuse PAVMs was recognized in light of this necessity for a better 
treatment approach.  
We extended the observations from the 2000 paper to additional 21 patients with 
diffuse PAVMs, and followed up on 15 out of the 16 previously reported patients (69). 
Furthermore, we preformed an extensive literature review of diffuse PAVMs, searching 
for other attempts to re-define the anatomy of diffuse PAVMs.  
 
Definition of Diffuse PAVMs 
Prior to the 2000 report, diffuse PAVMs were often called pulmonary telangiectases 
or microscopic arteriovenous fistulae, and were vaguely described as innumerable 
fistulae or “spidery” small vessels, distributed diffusely throughout both lungs.  
Classification of PAVMs into focal, multiple and diffuse has been around for 
decades (67, 96), but there have been no prior attempts to distinguish between various 
degrees of involvement of the lung with diffuse PAVMs. In the 2000 report, diffuse 
PAVMs were defined as affecting all segmental branches of one lobe (69). We observed 
that many patients with diffusely involved segmental arteries did not necessarily have all 
arteries of a single lobe affected- some were spared or much less involved. Therefore, we 
feel that it is more accurate to report diffuse involvement with respect to segments rather 
than lobes. We consider involvement as diffuse if at least 1 of the 18 lung segments is 
diffusely affected. Patients with only a small number of segments diffusely involved (2 or 
3) have a sustained rise in oxygen saturation after peripheral to central occlusion.  
It is important to note that multifocal PAVMs may be difficult to distinguish from 
diffuse ones, in fact, many of the PAVMs that were reported in previous studies as 
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diffuse were actually multifocal. The difference is that multifocal PAVMs respond well 
to TCE, such that their post-embolization pulmonary angiogram generally appears almost 
normal, and their oxygen saturation rises significantly. This does not happen with diffuse 
PAVMs, making them much more difficult to treat.  
 
Natural history of Diffuse PAVMs 
Patients with diffuse PAVMs have been found to present earlier in life, usually with 
exercise intolerance and profound cyanosis and appear to have a poor prognosis.  
 
Neurological Complications 
In patients with HHT, neurological complications are more frequently related to 
PAVM than to hemorrhagic cerebral AVM (101).  
Traditionally, neurological events occur in about 30% of patients with focal 
PAVMs (66).  Stroke/TIA occur in 10-20% of these patients(102), whereas cerebral 
abscesses have been found in about 10% (60, 102).  It has been pretty well shown that 
follow-up every 5 years is all that is necessary in these patients with focal PAVMs (72).  
In the small subset of HHT patients with diffuse PAVMs, these events are more 
common. Faughnan and colleagues reported the rates of 50% for stroke/TIA and 38% for 
cerebral abscesses (69).  In our study, in which we followed for additional 8 years fifteen 
out of the sixteen patients from Faughnan’s cohort (69), 5 patients (30%) had a stroke or 
TIA during the follow-up period, while brain abscess occurred in 2 patients (13%).  In the 
21 new patients that we followed from 1998-1996, strokes/TIAs occurred in 3 of them 
(14%), and two abscesses occurred in each of the 2 patients. Because of the higher risk of 
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neurological complications, among others, yearly follow-up is recommended in patients 
with diffuse PAVMs.  
Neurological manifestations generally result from: secondary polycythemia and 
hyperviscosity due to chronic hypoxia from right to left shunting, communication 
between the airways and pulmonary circulation during cough produces gas embolism and 
hemoptysis, and paradoxical emboli that pass through PAVMs (74). In patients with 
diffuse PAVMs, hypoxemia is more severe, leading to greater degree of polycythemia 
and hyperviscosity. In addition, since more PAVMs are present, there is a greater loss of 
capillary filter function. Therefore, an increased risk of neurological complications in 
patients with diffuse PAVMs is not surprising.  
Cerebral abscesses in HHT are frequently due to multiple anaerobic organisms and 
predominate in supratentorial areas of the brain (103). They were found to follow dental 
procedures in more than half the cases (69). In HHT, brain abscesses occur at a younger 
age than in the general population and may relapse (102). One of the deaths that occurred 
in our cohort was due to a brain abscess in a patient that did not seek medical attention in 
time. Any patient with PAVMs should seek medical attention for headache lasting more 
than 24 hours. In addition, due to the risk of infections, antibiotic prophylaxis prior to 
potentially bacteremic procedures is recommended in all HHT patients with a positive 
bubble study, including those without a visible PAVM on imaging.  
 
Hemoptysis 
Hemoptysis in patients with diffuse PAVMs has emerged as an important symptom 
that requires further understanding. In our cohort, hemoptysis was associated with a URI 
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in most cases. If treated appropriately with antitussives, it rarely becomes massive 
(>100ml/day). As part of the hemoptysis work-up, bronchoscopy is performed to rule out 
telangiectasia of the tracheal bronchial mucosa.  
In a recent report by Brillet et al, about 40% of patients with previously treated 
focal PAVMs were found to have enlarged bronchial arteries (104). In this group of 
patients, the frequency of clinical events suggestive of lung infarction in the days or 
months after embolotherapy and the frequency of CT features suggestive of sequelae of 
lung infarction on CT angiograms were significantly higher than those observed in the 
group of patients without abnormal enlargement of systemic arteries. This supports the 
already suggested hypothesis that the treatment of focal PAVMs may induce ischemia, 
which could trigger enlargement of bronchial arteries supplying the PAVMs. Another 
hypothesis is that bronchial artery hypertrophy is a part of the HHT syndrome. We have 
empirically changed our treatment from central to peripheral occlusion, in hopes of 
avoiding bronchial artery enlargement and collateral filling of distal pulmonary arteries, 
and thus hemoptysis. In those patients that do not respond well to antitussives and 
progress to massive hemoptysis, the Yale center has been successful at controlling this 
symptom by performing bronchial embolotherapy (69, 100).  
Improved knowledge of the frequency of congenital and acquired systemic arterial 
supply of PAVMs, as well as predictive factors for the latter situation, requires precise 
mapping of systemic arteries before embolotherapy, which was not done in the above 
mentioned study by Brillet et al. Future studies investigating the role of bronchial 
embolotherapy are needed.  
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Mortality 
Patients with bilateral involvement have greater mortality than those with unilateral 
involvement. Six deaths occurred in our series, and neither age nor oxygen saturations 
were predictors of death. Three of the deaths were potentially preventable. One was due 
to massive hemoptysis and delay in seeking medical attention. The second one was in a 
patient with a history of brain abscess, who did not seek prompt medical attention for 
headache, which turned out to be a second abscess 21 years after the first one. Any 
patient with a PAVM should seek medical attention for headache lasting over 24 hours. 
Finally an infant with diffuse bilateral involvement died of cerebral hemorrhage, most 
likely secondary to an undiagnosed CAVM, further emphasizing the importance of 
screening all HHT patients for CAVMs during initial work-up. 
The remaining 3 patients died of liver complications, which likely occur due to 
shunting of poorly oxygenated blood through multiple liver AVMs. Up to 80% of HHT 
patients have liver shunts(4), which rarely cause symptoms due to high output failure 
(54). In our patients, 2 developed “liver disintegration”, a syndrome of liver hemorrhage, 
pain and elevated alkaline phosphatase (105). The last patient developed progressive 
ammonia intoxication without acute symptoms. Presently, in the United States, the 
United Network for Organ Sharing (UNOS) does not recognize HHT as an indication for 
liver transplant. 
  
Treatment of Diffuse PAVMs 
Before 1980, surgical resection was the only method of treatment of PAVMs (106, 
107), and it rarely still has a role in patients in whom right-to-left shunting persists after 
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embolization of all feasible vessels (44), or if a patient has severe contrast allergy, 
precluding angiography.  
Transcatheter embolization therapy has been the preferred method of treatment since the 
1980’s as it avoids major surgery, general anesthesia, and loss of pulmonary parenchyma 
and is technically-successful in over 98% of cases (71).  
In 2006, Pollak et al published their results regarding outcomes of TCE in 154 
patients with focal PAVMs (72). They had about a 3% reperfusion rate for focal PAVMs, 
which may occur due to recanalization of an embolized vessel, or growth of missed or 
previously small accessory artery.  
More difficult are the treatment considerations for patients with diffuse PAVMs.  
Lung transplantation has been reported in only a small number of patients. One of 
the patients from the 2000 cohort died in the lung transplant peri-operative period. There 
have been 2 case reports to date of lung transplantation as a therapeutic option for 
PAVMs unresponsive to other forms of treatment (108, 109). The first case reported was 
a double lung transplant in a patient with diffuse PAVMs, severe hypoxemia and multiple 
previous failed attempts of TCE (109). This patient had a satisfactory short-term 
outcome, but no follow-up has been published. The second case was a patient with 
bilateral multifocal PAVMs with a previous lobectomy and one AV fistula occlusion, 
who at 3 years post-transplantation of the right lung was performing normal daily 
activities with oxygen saturations of 99%, even during exercise. The potential for 
recurrence of the disease in the donor organ is still unknown.  Given the very small 
number of lung transplant cases in patients with PAVMs who are unresponsive to other 
forms of treatment, more long-term outcome data is needed.  Because of this lack of data 
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and because survival with disease is difficult to predict, we currently do not recommend 
lung transplantation as a therapeutic approach to diffuse PAVMs. 
Redistribution of pulmonary blood flow, by occluding the segmental arteries of an 
entire lobe has been used successfully and with improvement in oxygenation.  
Unfortunately, a late complication, such as hemoptysis due to bronchial artery 
hypertrophy has made this approach not ideal. Consequently, the Yale technique has 
changed empirically based on follow-up of patients since 2000, such that only those 
segmental arteries with diffuse involvement are occluded peripherally, from distal to 
proximal, with pushable fibered coils (99). Our primary indication for embolotherapy at 
initial evaluation of patients with diffuse PAVMs remains the same- occluding all focal 
PAVMs with arteries 3mm or larger (72).  In our series, large focal PAVMs were more 
commonly found in the bilateral group. Embolization of these arteries protects against 
paradoxical embolization, but not necessarily against bacterial embolization. Therefore, 
antibiotic prophylaxis remains necessary to cover potentially bacteremic procedures (72). 
The new Yale treatment approach to diffuse PAVMs is performed only in very 
symptomatic patients, such as those experiencing dyspnea and fatigue, in the absence of 
anemia as the underlying cause. Interestingly, many of our patients are relatively 
asymptomatic despite very low oxygen saturations, likely reflecting the absence of 
pulmonary hypertension or airway issues.  
Complications of embolization therapy include pleuritic chest pain, air embolism, 
with angina and bradycardia caused by air in the coronary arteries, and device migration 
(2, 68, 110). In experienced hands, complication rates as a result of embolotherapy are 
low, except for hemoptysis, which may or may not be due to TCE.  
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Pleuritic chest pain may develop in 10% of patients after embolization, usually 
developing 2 to 4 days after the procedure, often self-limited, and usually resolving 
within 1 to 2 days with simple analgesia or anti-inflammatories (2). 
Device migration has a previously reported incidence of 1.2% (66), but its 
incidence in experienced hands is lower (2, 68, 110), and did not occur in any of our 
patients. Migration of balloons or coils to the hepatic artery, the internal iliac artery, the 
femoral artery, the carotid artery and the left ventricle has been reported (68, 111-113). 
None of the reported migrations has resulted in permanent disability, although about half 
required some intervention, usually with an intravascular retrieval device or, rarely, 
emergency surgery (71, 112, 113). Device migration may be due to misjudgment of 
balloon location, use of a balloon or coil that is too small for the artery to be occluded, 
suboptimal fluoroscopic visualization, or complex anatomy with difficult access (68). 
Various techniques for fixing the coil position to prevent distal migration can be used in 
PAVMs with large feeding arteries (111). 
In our cohort, complications were overall less in the unilateral group and their 
response to TCE was superior to that in patients with bilateral involvement.  
As a result of a low, but significant risk of reperfusion after embolization, which 
results in recurrent risk of paradoxical embolization, monitoring for PAVM growth after 
treatment is necessary. With all the concern from radiation (114), we should be able to 
assess growth and monitor by less invasive means. Exercise testing measuring oxygen 
saturation might be a solution to this problem, and is currently being developed at Yale. 
Assessment of bronchial artery hypertrophy as a result of embolization and as a possible 
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cause for hemoptysis, is another important issue which will be studied in the near future 
at the Yale HHT Center.  
 
Recommendations 
Because of the small number of patients reported with diffuse PAVMs, it is still 
difficult to make concrete recommendations about their management. However, we 
firmly recommend yearly follow-up, given the increased morbidity and mortality 
associated with these patients.  
Embolization of PAVMs in patients with diffuse PAVMs does not improve their 
hypoxemia (as many untreated PAVMs remain), but may reduce the risk of neurological 
sequelae. Therefore, these patients have a fairly good prognosis with appropriate 
management, which should include embolotherapy of larger AVMs, and life-long 
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Figure 2. Yale HHT Center Recommendations: Screening and Management of Cerebral 
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Figure 3. Yale HHT Center Recommendations: Screening and Management of 
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                 4B. 
 
 
Figure 4A-B. Left anterior oblique selective right pulmonary angiogram early and late 
arterial images. A. Diffuse involvement of the posterior and medial segment arteries, 
while the anterior and lateral segments are uninvolved. B. In the late arterial phase, early 
venous drainage into the left atrium is seen from the diffusely involved posterior medial 
segments.  
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                      5A. 
 
 
                     5B. 
 
 
Figure 5A-B. Shallow anterior oblique views of super selective right pulmonary 
angiograms in late arterial phase. In both A (anterior segment) and B (lateral segment), 
diffuse involvement from each subsegmental branch is noted. At the end of each 
subsegmental branch are tiny, almost “telangiectasia type” abnormalities. The pulmonary 
veins from each of these segments are already opacified.  
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    6A.                                                                       6B.  
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        6E.                                                                      6F.  
            
 
Figure 6A-F.  Young patient with multifocal PAVM in right lung. Earlier in life surgical 
resection of her right superior segment had been performed. A (anterior) and B (lateral) 
right pulmonary angiograms are demonstrating small PAVMs distally in right lower lobe 
and right middle lobe. In C and D, super selective pulmonary angiogram in anterior 
segment of right lower lobe demonstrates multiple focal PAVMs with early venous 
drainage. In E and F, super selective pulmonary angiogram with catheter beyond right 
middle lobe and anterior segment of lower lobe demonstrates “normal” pulmonary artery 
anatomy following distal occlusion of each small focal PAVM. No early veins are seen and 
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                                 7B. 
 
 
Figure 7A-B.  Post-occlusion angiograms from patient in Figure 1 after peripheral 
occlusion of most involved segments in right lower lobe (posterior, anterior and lateral), 
demonstrating the new approach of occluding from distal to proximal, using “tightly” 
packed coils 
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Table 1. PATIENTS WITH UNILATERAL DIFFUSE PAVM 
        1980-1998 1998-2006   
PT HHT  Sex Age Stroke/TIA BA HEMO Stroke/TIA BA HEMO Y/F 
1 N M 33   Y         16 
2 Y F 31       Y     10 
                      
3 Y M 22         Y   4 
4 Y M 37             6 
5 Y F 10           Y 6 
6 N M 23       Y     1 
7 N M 25             1 
8 Y M 7           Y 6 
9 Y M 4             4 
10 Y M 7             <1 
PT=patient, N=no, Y=yes, Sex, F=female, M=male, Age= age in years at 
presentation, BA=brain abscess, HEMO= hemoptysis, Y/F=years of continuous follow-
up. Patients 1-2 reported in previous 
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Table 2. PATIENTS WITH BILATERAL DIFFUSE PAVM 
        1980-1998 1998-2006   
PT HHT  Sex Age Stroke/TIA BA HEMO Stroke/TIA BA HEMO Y/F 
11 N F 29             17 
12 Y F 24   Y Y     2 15* 
13 Y M 15 Y Y     Y   17* 
14 Y F 14   Y Y       5* 
15 Y F 39 Y     Y     14 
16 Y M 6 Y           5* 
17 Y F 42 Y Y         6* 
18 Y F 20 Y     Y Y 2 9 
19 Y F 17 Y     Y     22* 
20 Y M 20 Y         Y 26 
21 Y F 50 Y Y   Y     9 
22 N M 23             13 
23 N F 0.8             1.5* 
                      
24 Y F 12             3 
25 N F 0.5             0.4* 
26 Y F 43             5 
27 Y F 71       Y     3* 
28 Y F 6             4 
29 Y F 4             8 
30 Y F 49         2   9 
31 Y F 28             7 
32 Y F 5             5 
33 Y M 9             1 
34 Y M 15             16 
35 Y M 9             4 
36 Y F 31       Y 
1+1 spinal 
abscess   10 
N=no, Y=yes, Sex, F=female, M=male, Age= age in years at presentation, BA=brain abscess, 
HEMO= hemoptysis, Y/F=years of continuous follow-up. Patients 11-23 reported in previous 














Table 3.  PATIENTS WITH UNILATERAL DIFFUSE PAVM: DISTRIBUTION AND 
OXIMETRY 
      Right Left 
Focal 
PAVM O2 saturation 
PT HHT Sex >50% <50% >50% <50% Unil Bilat Initial Current 
1 N M Y       Y   85% 95% 
2 Y F Y           82% 90% 
                      
3 Y M       Y     91% 99% 
4 Y M       Y     88% 96% 
5 Y F Y           73% 82% 
6 N M       Y     92% 92% 
7 N M   Y         N/A N/A 
8 Y M   Y     Y   90% 93% 
9 Y M Y           92% 89% 
10 Y M   Y         71% 71%* 
PT=patient, Sex F=female, M=male, >50%=5 or more segments of right lung or 4 or 
more segments of left lung diffusely involved, <50% less than 5 segments of right 
lung or 4 or more segments of left lung diffusely involved, Unil=unilatera, 
Bilat=bilateral, N/A=not available.  Inital and current O2 saturations are values in 
room air, usually standing when first seen by us, and current values up to December 
2006. Patients 3-10 seen after 1998. *Patient 10 was subsequently treated at 
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Table 4.  PATIENTS WITH BIILATERAL DIFFUSE PAVM: DISTRIBUTION AND 
OXIMETRY 
      Right Left 
Focal 
PAVM O2 saturation 
PT HHT Sex >50% <50% >50% <50% Unil Bilat Initial Current 
11 N F Y   Y     Y 87% 93% 
12 Y F Y   Y     Y 71% 94% 
13 Y M Y   Y     Y 71% 86% 
14 Y F Y     Y     67% N/A 
15 Y F Y   Y     Y 85% 87% 
16 Y M Y   Y     Y 82% 81% 
17 Y F Y   Y     Y 84% 70% 
18 Y F Y   Y     Y 82% 92% 
19 Y F Y   Y   Y   86% 87% 
20 Y M Y   Y     Y 79% 74% 
21 Y F Y   Y     Y 84% 96% 
22 N M Y   Y       91% 87% 
23 N F Y   Y   Y   75% N/A 
                      
24 Y F Y   Y   Y   82% 76% 
25 N F Y   Y       77% 77% 
26 Y F Y   Y     Y 78% 89% 
27 Y F Y   Y     Y 86% 90% 
28 Y F Y     Y     74% 65% 
29 Y F Y   Y       67% 73% 
30 Y F Y   Y     Y 87% 76% 
31 Y F   Y Y       88% 82% 
32 Y F Y   Y       60% 68% 
33 Y M   Y   Y     83% 70% 
34 Y M Y     Y     86% 94% 
35 Y M Y   Y     Y 65% 73% 
36 Y F Y   Y   Y   83% 89% 
PT=patient, Sex F=female, M=male, >50%=5 or more segments of right lung or 4 or 
more segments of left lung diffusely involved, <50% less than 5 segments of right 
lung or 4 or more segments of left lung diffusely involved, Unil=unilatera, 
Bilat=bilateral, N/A=not available.  Inital and current O2 saturations are values in 
room air, usually standing when first seen by us, and current values up to December 
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